SH-ZCCDD-RGB
Zane Cohen Centre for Digestive Diseases
Donate

We build knowledge to improve treatment

Clinical Trial for a New Oral Medication in Crohn’s Disease

Details of Research

Contact:
Shlomit Boguslavsky, Clinical Research Coordinator
416-586-4800 ext. 4989
Shlomit.Boguslavsky@sinaihealth.ca

Primary Investigator: Dr. Hillary Steinhart

Enrolment: Ongoing

Mount Sinai Hospital is participating in a research study to understand the safety and effectiveness of an investigational medication for treating Crohn’s Disease.
This mediation is given orally (by mouth).

We are looking for individuals:

  • With Crohn's Disease.
  • Experiencing symptoms related to their Crohn’s Disease.
  • Have previously and/or currently not responded to one of the following standard treatments:
    - Corticosteroids (e.g. Prednisone, Budesonide)
    - Immunosuppressants (e.g., Imuran, Methotrexate, 6-MP)
    - Biologic Therapy (e.g., Remicade, Humira, Stelara)  

This study will last up to 4.5 years. Your Crohn’s Disease will be assessed and, if eligible, participants will be randomized in a 2:1 ratio to receive study medication or placebo ("dummy" drug). If your Crohn’s Disease has not improved by week 12 of the study, you may be eligible for the open-label (no placebo) portion of the study. Reimbursement will be provided for study-related travel expenses.